Phase II study of inotuzumab ozogamicin in MRD+ B-ALL

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic le...Подробнее

Inotuzumab ozogamicin for MRD-positive B-ALLПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...Подробнее

A Phase II adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed Ph+ ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...Подробнее

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALLПодробнее

What is the role of inotuzumab ozogamicin in ALLПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Phase II study shows blinatumomab achieves minimal residual disease response in ALLПодробнее

Relapsed/Refractory ALL: Inotuzumab OzogamicinПодробнее

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALLПодробнее